Is QIAGEN N.V. a good investment? QIAGEN N.V. (QIA.DE) is currently trading at 32.12 EUR. Market analysts have a consensus price target of 39.19 EUR. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 18.86. This valuation is generally in line with the broader market.
Earnings Schedule: QIAGEN N.V. is expected to release its next earnings report on Aug. 4, 2026. The market consensus estimate for Forward EPS is 2.25.
For income investors, QIAGEN N.V. pays a dividend yield of 0.92%. With a payout ratio of 13%, the dividend appears sustainable.
Yes, it pays an annual dividend of 0.30 EUR (0.92% yield).
QIAGEN N.V. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.
The next earnings date is projected to be Aug. 4, 2026. The company currently has a trailing EPS of 1.70.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
| Year | Total Dividends |
|---|---|
| ▸2027 |
2.39 EUR
|
| July 12, 2027 (estimated) | 0.3081 |
| Jan. 25, 2027 (estimated) | 2.0861 |
| ▸2026 |
2.39 EUR
|
| July 14, 2026 | 0.3081 |
| Jan. 8, 2026 | 2.0861 |
| ▸2025 |
1.41 EUR
|
| July 10, 2025 | 0.2277 |
| Jan. 29, 2025 | 1.1806 |
| ▸2024 |
1.20 EUR
|
| Jan. 30, 2024 | 1.1993 |
| ▸2017 |
1.04 EUR
|
| Jan. 25, 2017 | 1.0432 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| QIAGEN N.V. | Jul 14, 2026 | Paid | 0.30814 EUR |
| QIAGEN N.V. | Jan 08, 2026 | Paid | 2.086069 EUR |
| Split Date | Split Ratio to 1 |
|---|---|
| July 14, 2000 | 4.000000 |
| Jan. 25, 2017 | 0.962963 |
| Jan. 30, 2024 | 0.970000 |
| Jan. 29, 2025 | 0.972222 |
| Jan. 8, 2026 | 0.950000 |
Community Discussion